NEWS
-
PR
The current status and future perspectives of iPSC technology-based regenerative medicine for kidney diseases.
-
PR
Elucidation of mechanism of the production of erythropoietin for the development of new therapeutic agents for renal anemia
-
PR
A review article on the development of regenerative medicines for renal diseases
-
PR
A review article on the kidney organoids generated from iPS cells and their clinical applications
-
PR
Notice of joint research agreement with ABI CO., LTD.
-
PR
Notice of joint research agreement with NIKKISO CO., LTD.
-
PR
Notice of Conclusion of Joint Research Agreement with Kirin Holdings Co., Ltd.
-
PR
Succeeded in producing a large amount of tissue that is the basis of renal collecting duct
-
MEDIA
Featured in Nikkei newspaper, its electronic version, Asahi Shimbun DIGITAL and many other media.
-
PR
Announcement of financing and business alliance
-
PR
Regenerate renal tissue from multiple renal progenitor cells differentiated from human iPS cells separately
-
PR
Immobilization of low molecular weight compounds that replace BMP7 in the expansion method of renal progenitor cells
-
PR
The company name has been changed from RegeNephron Co., Ltd. to Rege Nephro Co., Ltd.
-
PR
Rege Nephron Co., Ltd. was established.
-
MEDIA
Published in the Nikkei newspaper and the electronic version.
-
The current status and future perspectives of iPSC technology-based regenerative medicine for kidney diseases.
-
Elucidation of mechanism of the production of erythropoietin for the development of new therapeutic agents for renal anemia
-
A review article on the development of regenerative medicines for renal diseases
-
A review article on the kidney organoids generated from iPS cells and their clinical applications
-
Notice of joint research agreement with ABI CO., LTD.
-
Notice of joint research agreement with NIKKISO CO., LTD.
-
Notice of Conclusion of Joint Research Agreement with Kirin Holdings Co., Ltd.
-
Succeeded in producing a large amount of tissue that is the basis of renal collecting duct
-
Announcement of financing and business alliance
-
Regenerate renal tissue from multiple renal progenitor cells differentiated from human iPS cells separately
-
Immobilization of low molecular weight compounds that replace BMP7 in the expansion method of renal progenitor cells
-
The company name has been changed from RegeNephron Co., Ltd. to Rege Nephro Co., Ltd.
-
Rege Nephron Co., Ltd. was established.
